Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.
Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.
One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.
Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.
Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.
Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.
Artelo Biosciences (NASDAQ: ARTL) announced a Mitacs Accelerate grant that will fund 50% of research costs for evaluating ART26.12 as a potential treatment for anxiety disorders. The grant supports preclinical research in collaboration with Dr. Steven Laviolette at the University of Western Ontario. ART26.12 aims to inhibit Fatty Acid Binding Protein 5 (FABP5), potentially increasing anandamide levels, which may enhance treatment efficacy for anxiety. The funding will also aid in pharmacology research and biomarker identification related to stress response.
Artelo Biosciences (NASDAQ: ARTL) has received Clinical Trial Authorization (CTA) in the UK for its Cancer Appetite Recovery Study (CAReS) aimed at treating cancer-related anorexia. The Phase 1/2 trial will evaluate the efficacy and safety of synthetic cannabinoid ART27.13, targeting a market of over $2 billion. With a recruitment goal of 43 patients, the company plans to initiate enrollment before year-end 2020, despite operational challenges posed by the Covid-19 pandemic. The trial addresses a significant unmet need, as cancer-related anorexia affects over 60% of advanced cancer patients.
Artelo Biosciences (NASDAQ:ARTL), a biopharmaceutical company, will present at the Virtual Fall Investor Summit from November 16-18, 2020. CEO Gregory D. Gorgas is scheduled to speak on November 18 at 11:30 a.m. ET. The presentation will be available for live streaming and replay. Attendees can schedule one-on-one meetings via video calls during the summit. Artelo focuses on developing therapeutics targeting the endocannabinoid system for conditions like anorexia, cancer, and pain. For details, visit www.artelobio.com.
Artelo Biosciences (NASDAQ: ARTL) recently announced the closing of a $7.6 million underwritten public offering and received ethics approval for the CAReS study of ART27.13 in the UK. The company expanded its exclusive worldwide license with Stony Brook University for the FABP5 inhibitor platform aimed at treating cancer, pain, and inflammation. For the fiscal year ending August 31, 2020, Artelo reported a net loss of $4.65 million or $1.26 per share, an increase from the previous year, and had cash reserves of approximately $2.14 million.
Artelo Biosciences (NASDAQ: ARTL) has announced a significant advance in the treatment of psychological disorders, filing a patent for FABP5 inhibitors aimed at conditions like anxiety and PTSD. Recent preclinical data indicate that inhibiting FABP5 increases anandamide levels in critical brain regions, potentially providing a new therapeutic pathway with fewer side effects compared to current treatments. This is particularly relevant as COVID-19 may heighten PTSD risks. The company has also expanded its patent estate by acquiring rights to third-generation FABP5 inhibitors.
Artelo Biosciences (NASDAQ: ARTL) announced the closing of an underwritten public offering, raising approximately $7.6 million. The offering consisted of 10,120,000 units, each priced at $0.75, including common stock and warrants with the same exercise price expiring after five years. This offering included the full exercise of the underwriter's over-allotment option. Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager. The issuance was registered under SEC Form S-1 effective October 8, 2020.
Artelo Biosciences, Inc. (NASDAQ: ARTL) announced an underwritten public offering, aiming for gross proceeds of approximately $6.6 million. The offering includes 8.8 million units priced at $0.75 per unit, each unit consisting of one share of common stock and a warrant with an identical exercise price, expiring in five years. The closing is anticipated on or around October 14, 2020. Additionally, underwriters have a 45-day option to purchase up to 1.32 million additional shares and warrants for over-allotments. This offering follows SEC registration (File No. 333-249083) approved on October 8, 2020.
Artelo Biosciences, Inc. (NASDAQ: ARTL) announced its participation in the H.C. Wainwright Annual Global Investment Conference, taking place virtually from September 14-16, 2020. CEO Gregory D. Gorgas is set to present on September 15 at 3:30 p.m. Eastern Time, with a live webcast available on the event platform. The company focuses on developing therapeutics targeting the endocannabinoid system to address unmet medical needs in various conditions such as cancer, pain, and anorexia. More details can be found on their website.
Artelo Biosciences, Inc. (NASDAQ: ARTL) will participate in the 3rd Annual International Cannabinoid Derived Pharmaceuticals Summit from September 15-17, 2020. CEO Gregory D. Gorgas will discuss intellectual property strategies for cannabinoid drug development on September 15, while Interim CSO Andy Yates, PhD, will present on clinical trial design and the ART27.13 program for cancer-related anorexia on September 16. This summit aims to address challenges in cannabinoid pharmaceutical development, fostering critical discussions among industry specialists.
Artelo Biosciences, Inc. (NASDAQ:ARTL) will present at the LD 500 Virtual Investor Conference from September 1-4, 2020. CEO Gregory D. Gorgas is scheduled to speak on September 1 at 10:20 a.m. Eastern Time. The presentation will be available via webcast. Artelo is focused on developing therapeutics targeting the endocannabinoid system for conditions like cancer and pain. Attendees can schedule one-on-one meetings with the company through the conference registration platform.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What does Artelo Biosciences do?
Where is Artelo Biosciences headquartered?
What are the main therapeutic areas Artelo Biosciences focuses on?
What is ART12.11?
What is ART26.12?
What is ART27.13?
What recent achievement has ART12.11 demonstrated?
What progress has been made in the ART26.12 program?
Who leads Artelo Biosciences?
Where can I find more information about Artelo Biosciences?
